The Six-Month Windfall: Transforming Pediatric Exclusivity from Regulatory Hurdle to Strategic Asset
ð¨ The Hidden Goldmine in Pediatric Drug Exclusivity: Are Pharma Giants Missing Out? ð¨
Imagine a world where a regulatory hurdle transforms into a strategic goldmine—where a six-month extension could mean hundreds of millions in additional revenue…
